



# Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants

## SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: Sanger sequencing validation of the TP53 variant identified in P65.** (A) Screenshot of the sequences reads aligned to the reference genome using the Integrative Genomics Viewer (IGV). Left panel non-tumor tissue, right panel tumor tissue. (B) Sanger sequencing chromatograms of the TP53 mutation.



Supplementary Figure 2: Venn diagram listing the overlap of genes between the ECCP and the CCP.

Supplementary Table 1: Comparison of Results of WES, CCP, and ECCP Analyses for P65.

See Supplementary File 1

Supplementary Table 2: DL Variants Identified by ECCP.

See Supplementary File 2

**Supplementary Table 3: DL2 Whole Genome Sequencing Variant Results.**

**See Supplementary File 3**

**Appendix 1: List of genes included on the Einstein Custom Cancer Panel.**

**See Supplementary Appendix 1**

**Appendix 2: List of variants identified by WES for P65.**

**See Supplementary Appendix 2**

**Appendix 3: List of genes included on the Comprehensive Cancer Panel.**

**See Supplementary Appendix 3**